BWA
PDSB icon

Basecamp Wealth Advisors’s PDS Biotechnology PDSB Stock Holding History

Basecamp Wealth Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332 Hold
377
– – ﹤0.01% 1689
2026
Q1 		$228 Hold
377
– – ﹤0.01% 1845
2025
Q4 		$290 Buy
+377
New +$340 ﹤0.01% 1684

Other funds holding PDSB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Basecamp Wealth Advisors's PDSB Position: Q2 2026 in Review

Basecamp Wealth Advisors held its PDS Biotechnology (PDSB) position steady in Q2 2026 at 377 shares worth $332. The position accounts for ﹤0.01% of the portfolio, ranked #1689.

Basecamp Wealth Advisors first reported a position in PDSB in Q4 2025 and has held it in 3 quarters since. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

  • Basecamp Wealth Advisors held 377 shares of PDS Biotechnology worth $332 as of Q2 2026.
  • Basecamp Wealth Advisors left its PDS Biotechnology share count unchanged in Q2 2026.
  • PDS Biotechnology made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1689 holding.
  • Basecamp Wealth Advisors first reported a position in PDS Biotechnology in Q4 2025 and has held it in 3 quarters since.
  • 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.